17,000+ key IP decision-makers rely on Life Sciences IP Review (LSIPR) as their daily source of news in the life sciences, biotechnology and pharmaceutical industry. LSIPR offers IP professionals a single point of contact to stay on top of industry trends and developments. Readers of LSIPR include IP professionals from leading global organisations such as: Novartis, Johnson & Johnson, Astra Zeneca, Teva, Boeringher Ingelheim, Pfizer, Alnylam Pharmaceuticals, Astellas Pharma, Genentech, Millipore Sigma, GSK, Prolacta Bioscience, Amunix Pharmaceuticals, BioInfi, Merck and more. To sign up to receive our free e-newsletter, covering the latest industry news – click here: